Doctor invests in AI chatbot after using it for wife's cancer diagnosis.

Healz AI, a specialized oncology navigation platform, is gaining traction as a clinical decision-support tool after a documented case demonstrated its capacity to accelerate rare disease diagnosis. In fall 2025, Atlanta psychiatrist Dr. Munjal Shroff utilized the application while his wife navigated unexplained symptoms initially misattributed to autoimmune conditions. After uploading extensive medical records, the AI recommended a second opinion at MD Anderson Cancer Center, prompting a consultation that ultimately confirmed a rare T-cell lymphoma. Recognizing the platform precision and clinical utility, Dr. Shroff transitioned from a heavy user to a financial investor, a decision that aligns with Healz AI early-stage growth trajectory. Founded by co-CEOs Igor Demishev and Alex Plat, Healz AI operates as a supplement to human oncologists rather than a diagnostic replacement. The platform leverages existing large language models layered with a proprietary memory architecture capable of ingesting thousands of medical documents. To counter common generative AI pitfalls, the system employs a root-cause reasoning mode that asks up to twenty targeted symptom questions before generating recommendations. The initiative is backed by Recursive Superintelligence cofounder Alexey Dosovitskiy, whose firm recently raised over $650 million at a $4.65 billion valuation. Dosovitskiy cited healthcare latency in adopting foundational AI advances as a primary catalyst for his investment, noting that mature underlying models are now ready for clinical productization. Commercially, Healz AI reports strong engagement metrics within its niche demographic. As of early September, the company reached $100,000 in annual recurring revenue, with its user base comprising 97 percent cancer patients and a seventy percent monthly retention rate. The platform continues to expand its feature set to include treatment comparison, specialist matching, and scan interpretation. While Dr. Shroff acknowledged occasional minor inaccuracies in treatment monitoring, he emphasized that the AI significantly reduced diagnostic delays and improved patient confidence during complex clinical discussions. Healz AI is currently preparing for a follow-up funding round as it scales its oncology-focused workflow. The company trajectory underscores a broader industry shift toward specialized, medically verified AI assistants designed to augment, rather than automate, high-stakes healthcare decision-making.